Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapy
Objective: Severe exacerbations in alpha-1-antitrypsin (AAT)-deficient patients with chronic obstructive pulmonary disease (COPD) and/or emphysema are a major cause of hospitalization. A multicentre, observational, retrospective study was undertaken to evaluate the effect of continuous AAT augmentat...
Main Authors: | Juan Carlos Barros-Tizón, María Luisa Torres, Ignacio Blanco, María Teresa Martínez |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2012-04-01
|
Series: | Therapeutic Advances in Respiratory Disease |
Online Access: | https://doi.org/10.1177/1753465812438387 |
Similar Items
-
Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency
by: Irina Petrache, et al.
Published: (2009-05-01) -
Mineralization of alpha-1-antitrypsin inclusion bodies in Mmalton alpha-1-antitrypsin deficiency
by: Francesco Callea, et al.
Published: (2018-05-01) -
Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications
by: Chapman KR, et al.
Published: (2018-01-01) -
Augmentation therapy for emphysema due to alpha-1-antitrypsin deficiency
by: Gema Tirado-Conde, et al.
Published: (2008-02-01) -
Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies
by: Adriano R. Tonelli, et al.
Published: (2010-10-01)